Drugs / 111Indium CHX-A
111Indium CHX-A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT01445054 | Mar 2007 → Aug 2014 | breast cancer, colorectal cancer, lung cancer, prostate cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 111Indium CHX-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01445054 ↗ |
| Known as | (111)Indium-trastuzumab | “Whereas trastuzumab therapy is generally only useful in tumors that highly express HER2/Neu (Erb2), (111)In-CHX-A DTPA trastuzumab (henceforth (111)Indium-trastuzumab ) will...” NCT01445054 ↗ |
| Known as | CHX-A DTPA-trastuzumab | “We have developed a chelated form of trastuzumab, CHX-A DTPA-trastuzumab, that can bind a number of radioisotopes including (111)In, (212), (213)Bi, (212)Pb (86), (90)Y and...” NCT01445054 ↗ |
| Modality | Diagnostic / imaging agent | “followed by scanning with a gamma camera that detects the radioactivity in the Indium-Herceptin.” NCT01445054 ↗ |
| Route | Intravenous | “111Indium CHX-A will be administered intravenously over a 10-15 minute period using an intravenous catheter” NCT01445054 ↗ |